Oral Prednisolone Versus Posterior Sub-Tenon Triamcinolone for Acute Ocular VKH
Key facts
- Who runs it
- Benha University
- Where
- Egypt1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 30 people enrolled
- Started
- 1 Jan 2021
- Ended
- 1 Dec 2025
- Type of study
- Observational, 2 groups
- Record updated
- 12 February 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- Age ≥18 years; Diagnosis of definite or probable acute ocular Vogt-Koyanagi-Harada (VKH) disease; Active intraocular inflammation (choroiditis, serous retinal detachment, or panuveitis); No prior treatment for the current VKH episode; Minimum follow-up of 6 months with complete medical records, including BCVA and OCT data
Who cannot take part
- Prior systemic or periocular corticosteroid therapy for VKH; Use of immunosuppressive or biologic agents at presentation; Pre-existing glaucoma, ocular hypertension, or advanced cataract; Retinal diseases affecting visual outcomes (e.g., diabetic retinopathy, age-related macular degeneration); Incomplete medical records or missing OCT/BCVA data
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Vogt-Koyanagi-Harada (VKH) disease is a rare autoimmune disorder characterized by bilateral ocular inflammation that may lead to serous retinal detachment and permanent visual impairment if not promptly treated. Systemic corticosteroids are commonly used as first-line therapy; however, periocular corticosteroid administration has been proposed as an alternative approach that may reduce systemic adverse effects.
Read full original descriptionShow less
This retrospective cohort study reviewed the medical records of patients with acute ocular VKH disease to compare two initial treatment strategies: systemic oral prednisolone and posterior sub-Tenon triamcinolone acetonide (PST/STA). The primary objective was to evaluate control of ocular inflammation three months after treatment initiation. Secondary objectives included assessment of visual acuity changes over six months, anatomical recovery on optical coherence tomography (OCT), recurrence of inflammation, need for additional therapy, and treatment-related adverse events.
The 2 groups in the trial
- Oral Prednisolone Group
Patients received oral prednisolone at 1 mg/kg/day (maximum 80 mg/day) as initial therapy for acute ocular VKH. The full dose was given for \~1 week followed by gradual taper over 3-6 weeks. Topical corticosteroids and cycloplegics were allowed as adjunct therapy.
- Posterior Sub-Tenon Triamcinolone (PST/STA) Group
Patients received a posterior sub-Tenon injection of triamcinolone acetonide (40 mg/1 mL) as initial therapy for acute ocular VKH. A second injection at 4-6 weeks was administered if residual inflammation persisted. Systemic steroids were not used unless rescue criteria were met.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Retrospective Comparative Cohort Study Evaluating the Efficacy, Anatomical Outcomes, Recurrence Rates, and Safety of Oral Prednisolone Versus Posterior Sub-Tenon Triamcinolone Acetonide as Initial Therapy in Acute Ocular Vogt-Koyanagi-Harada Disease
- Publications
- Record updated
- 12 February 2026